Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

By M. Lebwohl, B. Strober, A. Menter, K. Gordon, J. Węgłowska, L. Puig, K. Papp, L. Spelman, D. Toth, F. Kerdel and 25 more. New England Journal of Medicine, 2015

761 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/395d9ca3310305bfccd0d6549fd0a6d7068d5518

Citations in the corpus

• Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies (2017, neutral): “Three randomized, double-blind, placebo-controlled phase III studies evaluated the efficacy of brodalumab for the treatment of moderate-to-severe plaque psoriasis: AMAGINE-1, AMAGINE-2, and AMAGINE-3.”